Who
Mark C. McKenna
Director
Company insider
Files Form 4 as: Director, Apogee Therapeutics; Other, Freenome; Director, Spyre Therapeutics; Director, NewAmsterdam Pharma Company; Other, BridgeBio Oncology Therapeutics; Chairman, President and CEO, Prometheus Biosciences; President, Salix, Bausch Health Companies.
In numbers
- Trades disclosed
- 82
- Buys
- 1
- Sells
- 8
- Bought
- $991K
- Sold
- $15.2M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 8 Jan 2019
- Last trade
- 3 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —20,000 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —150,000 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —150,000 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —20,000 | filing |
| 20 Jul 2026filed 22 Jul 2026 | FRNM FreenomeDiagnostics & Labs | SEC FORM 4 Code C | —30,000 | filing |
| 20 Jul 2026filed 22 Jul 2026 | FRNM Freenomeoption or derivative · Diagnostics & Labs | SEC FORM 4 Code C | —30,000 | filing |
| 20 Jul 2026filed 22 Jul 2026 | FRNM Freenomeoption or derivative · Diagnostics & Labs | SEC FORM 4 Code C | —30,000 | filing |
| 20 Jul 2026filed 22 Jul 2026 | FRNM FreenomeDiagnostics & Labs | SEC FORM 4 Code C | —30,000 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,026 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,026 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —3,400 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
News
Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)BHC · dailypolitical.com · 13 Oct 2026Contrasting Bausch Health Cos (NYSE:BHC) and Journey Medical (NASDAQ:DERM)BHC · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Mark C. McKenna; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.